TCRT Stock Explodes Higher As Traders Chase Volatility

Alaunos Therapeutics Inc. stocks have been trading up by 67.62 percent amid heightened optimism over its cutting-edge oncology pipeline.

Live Update At 08:32:27 EDT: On Tuesday, October 13, 2026 Alaunos Therapeutics Inc. stock [NASDAQ: TCRT] is trending up by 67.62%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Alaunos Therapeutics Inc., trading under ticker TCRT, is a micro-cap biotech name that trades more on hope and momentum than on current fundamentals. The latest report shows only about $5,000 in revenue, yet a massive loss of roughly $952,000 for the quarter. That kind of gap gives TCRT a profit margin deep in the red and tells traders the core business is still very early and very expensive.

The cash picture is tight. TCRT ended the period with just $124,000 in cash and negative working capital of about $198,000. With a current ratio of 0.8 and a quick ratio near 0.1, Alaunos Therapeutics Inc. does not have a wide safety net. The company has no long-term debt, but that usually means one thing for a story like TCRT: dilution risk stays on the table.

Valuation is also stretched versus sales, with a price-to-sales ratio near 957. For traders, that screams “story stock.” The numbers say TCRT is highly speculative. Any big price swings are more about trading psychology, liquidity, and sector sentiment than about steady business growth.

Why Traders Are Watching TCRT’s Wild Price Action

TCRT’s chart is exactly what short-term traders look for when they want volatility. On the daily time frame, Alaunos Therapeutics Inc. slid from the mid-$1s to the $0.70s, then suddenly reversed. In the latest session, TCRT closed at $1.05 after opening near $0.78. That’s a huge range day, and it signals a clear shift in control from sellers to aggressive momentum traders.

Zoom in to the intraday action and the story gets even louder. TCRT was trading around $1 at 04:00, then went nearly vertical. Within a few hours, Alaunos Therapeutics Inc. ripped past $2, then spiked toward the mid-$2s, and whipped back and forth with $0.30–$0.50 swings in minutes. Moves like that tell traders a lot of orders are chasing the tape, both long and short.

For active small-cap traders, this is classic “hot money” behavior. TCRT becomes a battlefield where breakout chasers, dip buyers, and short sellers all collide. The underlying financials are weak, but that often helps the trading game — it lowers the bar for rumors, sector strength, or any small positive data point to trigger oversized moves.

Alaunos Therapeutics Inc. now sits in a spot where prior resistance around $1.20–$1.30 on the daily chart turns into a key area to watch. If TCRT holds above $1, momentum traders may keep recycling it as a go-to volatility play. If it fails there, late longs will rush for the exits, and those same levels can flip into resistance again.

Conclusion

TCRT is not a slow, steady compounder. Alaunos Therapeutics Inc. is a tiny biotech with minimal revenue, heavy quarterly losses near $952,000, and a very limited cash cushion. The balance sheet sends a clear message to traders: this is a high-risk, high-uncertainty story, where capital raises and sharp sentiment swings are part of the game.

At the same time, the price action is exactly what active traders study for years. TCRT has shown powerful intraday waves, with the stock running from sub-$1 levels to the mid-$2s in premarket before pulling back. Those kinds of moves create opportunity if you stay disciplined and focus on risk first. Support around $1 and overhead zones near $1.50–$2 are important technical lines many TCRT traders will map out on their charts.

For anyone watching Alaunos Therapeutics Inc., the message is simple: respect the volatility. Have a clear plan before entering, and do not fall in love with the story when the financials still scream “speculation.” As millionaire penny stock trader and teacher Tim Sykes, says, “Cut losses quickly, let profits ride, and don’t overtrade.”. He emphasizes that in this kind of fast-moving trading environment, strict rules and emotional control are essential. Tim Sykes says it best: “The market doesn’t care about your opinion, it cares about your discipline.” TCRT rewards that discipline — and punishes traders who forget it. This analysis is for educational and research purposes only, and every trader must make their own decisions.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks